Compare iShares International Treasury Bond ETF (IGOV) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Medpace Holdings Inc — how do they compare? iShares International Treasury Bond ETF trades at $40.44, while Medpace Holdings Inc trades at $519.93 (market cap $15.08B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IGOV | MEDP | |
|---|---|---|
52-Week High | $43.09 | $620.59 |
52-Week Low | $40.54 | $308.88 |
Market Cap | — | $15.08B |
Sector | — | Technology |
Enterprise Value | — | $14.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV, trading at $40.68, is experiencing a slight decline of 0.22% today amid a bearish technical signal, with moving averages indicating strong selling pressure. The stock lacks available fundamental data such as P/E and profit margins, while recent news highlights significant downside risks from global inflationary pressures affecting its bond holdings.
The outlook for IGOV is cautious due to high duration exposure amplifying capital losses in a rising rate environment. Investment opportunities are limited without clear financial metrics, and risks include persistent energy issues and geopolitical tensions that could further impact performance.
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
